This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, J.
Right arrow Articles by Andes, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, J.
Right arrow Articles by Andes, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2006, p. 1570-1572, Vol. 50, No. 4
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.4.1570-1572.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Voriconazole Therapeutic Drug Monitoring

J. Smith,1 N. Safdar,1 V. Knasinski,1 W. Simmons,2 S. M. Bhavnani,3 P. G. Ambrose,3 and D. Andes1,4*

University of Wisconsin, Department of Medicine, Section of Infectious Diseases, Madison, Wisconsin,1 University of Wisconsin, Department of Pharmacy, Madison, Wisconsin,2 Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, New York,3 University of Wisconsin, Department of Medical Microbiology and Immunology, Madison, Wisconsin4

Received 22 September 2005/ Returned for modification 4 December 2005/ Accepted 9 January 2006

We report on 28 patients who underwent voriconazole monitoring because of disease progression or toxicity. A relationship (P < 0.025) between disease progression and drug concentration was detected. Favorable responses were observed in 10/10 patients with concentrations above 2.05 µg/ml, while disease progressed in 44% (n = 18) of patients with concentrations below 2.05 µg/ml.

* Corresponding author. Mailing address: 600 Highland Avenue, Room H4/572, Madison, WI 53792. Phone: (608) 263-1545. Fax: (608) 263-4464. E-mail: dra{at}medicine.wisc.edu.

Antimicrobial Agents and Chemotherapy, April 2006, p. 1570-1572, Vol. 50, No. 4
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.4.1570-1572.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Trifilio, S. M., Yarnold, P. R., Scheetz, M. H., Pi, J., Pennick, G., Mehta, J. (2009). Serial Plasma Voriconazole Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation. Antimicrob. Agents Chemother. 53: 1793-1796 [Abstract] [Full Text]  
  • Segal, B. H. (2009). Aspergillosis. NEJM 360: 1870-1884 [Full Text]  
  • Freifeld, A., Proia, L., Andes, D., Baddour, L. M., Blair, J., Spellberg, B., Arnold, S., Lentnek, A., Wheat, L. J. (2009). Voriconazole Use for Endemic Fungal Infections. Antimicrob. Agents Chemother. 53: 1648-1651 [Abstract] [Full Text]  
  • Parize, P., Chandesris, M.-O., Lanternier, F., Poiree, S., Viard, J.-P., Bienvenu, B., Mimoun, M., Mechai, F., Mamzer, M.-F., Herman, P., Bougnoux, M.-E., Lecuit, M., Lortholary, O. (2009). Antifungal Therapy of Aspergillus Invasive Otitis Externa: Efficacy of Voriconazole and Review. Antimicrob. Agents Chemother. 53: 1048-1053 [Abstract] [Full Text]  
  • Andes, D., Pascual, A., Marchetti, O. (2009). Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications. Antimicrob. Agents Chemother. 53: 24-34 [Full Text]  
  • Howard, A., Hoffman, J., Sheth, A. (2008). Clinical Application of Voriconazole Concentrations in the Treatment of Invasive Aspergillosis. The Annals of Pharmacotherapy 42: 1859-1864 [Abstract] [Full Text]  
  • Hafner, V., Albermann, N., Haefeli, W. E., Ebinger, F. (2008). Inhibition of Voriconazole Metabolism by Chloramphenicol in an Adolescent with Central Nervous System Aspergillosis. Antimicrob. Agents Chemother. 52: 4172-4174 [Abstract] [Full Text]  
  • Pasqualotto, A C, Shah, M, Wynn, R, Denning, D W (2008). Voriconazole plasma monitoring. Arch. Dis. Child. 93: 578-581 [Abstract] [Full Text]  
  • Yakiwchuk, E. M, Foisy, M. M, Hughes, C. A (2008). Complexity of Interactions Between Voriconazole and Antiretroviral Agents. The Annals of Pharmacotherapy 42: 698-703 [Abstract] [Full Text]  
  • Goodwin, M. L., Drew, R. H. (2008). Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 61: 17-25 [Abstract] [Full Text]  
  • Weiler, S., Zoller, H., Graziadei, I., Vogel, W., Bellmann-Weiler, R., Joannidis, M., Bellmann, R. (2007). Altered Pharmacokinetics of Voriconazole in a Patient with Liver Cirrhosis. Antimicrob. Agents Chemother. 51: 3459-3460 [Full Text]  
  • Li, Y., Nguyen, M. H., Derendorf, H., Cheng, S., Clancy, C. J. (2007). Measurement of Voriconazole Activity against Candida albicans, C. glabrata, and C. parapsilosis Isolates Using Time-Kill Methods Validated by High-Performance Liquid Chromatography. Antimicrob. Agents Chemother. 51: 2985-2987 [Abstract] [Full Text]  
  • Freifeld, A., Arnold, S., Ooi, W., Chen, F., Meyer, T., Wheat, L. J., Smedema, M., Lemonte, A., Connolly, P. (2007). Relationship of Blood Level and Susceptibility in Voriconazole Treatment of Histoplasmosis. Antimicrob. Agents Chemother. 51: 2656-2657 [Full Text]  
  • Dodds Ashley, E. S., Zaas, A. K., Fang, A. F., Damle, B., Perfect, J. R. (2007). Comparative Pharmacokinetics of Voriconazole Administered Orally as either Crushed or Whole Tablets. Antimicrob. Agents Chemother. 51: 877-880 [Abstract] [Full Text]  
  • Thiel, M. A., Zinkernagel, A. S., Burhenne, J., Kaufmann, C., Haefeli, W. E. (2007). Voriconazole Concentration in Human Aqueous Humor and Plasma during Topical or Combined Topical and Systemic Administration for Fungal Keratitis. Antimicrob. Agents Chemother. 51: 239-244 [Abstract] [Full Text]  
  • Pascual, A., Nieth, V., Calandra, T., Bille, J., Bolay, S., Decosterd, L. A., Buclin, T., Majcherczyk, P. A., Sanglard, D., Marchetti, O. (2007). Variability of Voriconazole Plasma Levels Measured by New High-Performance Liquid Chromatography and Bioassay Methods. Antimicrob. Agents Chemother. 51: 137-143 [Abstract] [Full Text]  
  • Trifilio, S., Pennick, G., Pi, J., Zook, J., Golf, M., Kaniecki, K., Mehta, J. (2006). Monitoring Plasma Voriconazole Levels May Be Essential To Avoid Subtherapeutic Levels.. ASH ANNUAL MEETING ABSTRACTS 108: 594-594 [Abstract] [Full Text]  
  • Trifilio, S., Singhal, S., Williams, S., Winter, J., Tallman, M., Gordon, L., Frankfurt, O., Evens, A., Mehta, J. (2006). Breakthrough Fungal Infections after Allogeneic Hematopoietic Stem Cell Transplantation in Patients on Prophylactic Voriconazole.. ASH ANNUAL MEETING ABSTRACTS 108: 2849-2849 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»